Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials.
1. Cover image - p. iv 2. Title page - p. iv 3. Table of Contents - p. iv 4. Copyright - p. iv 5. Contributors - p. ix 6. About the Editors - p. xiii 7. About the Series Editor - p. xvii 8. Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy” - p. xix 9. Preface - p. xxi 10. Chapter 1: EGFR and HER2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. xxi 11. Chapter 2: BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 11 12. Chapter 3: VEGFR Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 27 13. Chapter 4: ALK Tyrosine Kinase Inhibitors in Drug Sensitization - p. 43 14. Chapter 5: STAT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 52 15. Chapter 6: FLT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 65 16. Chapter 7: Collagen Signaling in Cancer - p. 88 17. Chapter 8: Bruton's Tyrosine Kinase (BTK) Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 108 18. Chapter 9: CDK Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 124 19. Chapter 10: Bcl-2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 149 20. Chapter 11: Small Molecule Chemosensitizing Agents: Polo-Like Kinase 1 (Plk1), BRAF and Janus Kinase (JAK) Inhibitors - p. 168 21. Chapter 12: PI3K/AKT Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 185 22. Chapter 13: Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 205 23. Chapter 14: Combining PI3K/Akt/mTOR Inhibition With Chemotherapy - p. 228 24. Chapter 15: MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 242 25. Index - p. 267
Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials.
1. Cover image - p. iv 2. Title page - p. iv 3. Table of Contents - p. iv 4. Copyright - p. iv 5. Contributors - p. ix 6. About the Editors - p. xiii 7. About the Series Editor - p. xvii 8. Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy” - p. xix 9. Preface - p. xxi 10. Chapter 1: EGFR and HER2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. xxi 11. Chapter 2: BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 11 12. Chapter 3: VEGFR Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 27 13. Chapter 4: ALK Tyrosine Kinase Inhibitors in Drug Sensitization - p. 43 14. Chapter 5: STAT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 52 15. Chapter 6: FLT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 65 16. Chapter 7: Collagen Signaling in Cancer - p. 88 17. Chapter 8: Bruton's Tyrosine Kinase (BTK) Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 108 18. Chapter 9: CDK Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 124 19. Chapter 10: Bcl-2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 149 20. Chapter 11: Small Molecule Chemosensitizing Agents: Polo-Like Kinase 1 (Plk1), BRAF and Janus Kinase (JAK) Inhibitors - p. 168 21. Chapter 12: PI3K/AKT Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 185 22. Chapter 13: Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 205 23. Chapter 14: Combining PI3K/Akt/mTOR Inhibition With Chemotherapy - p. 228 24. Chapter 15: MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy - p. 242 25. Index - p. 267
